Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies

Oncologist

Volumn 18, Issue 7, 2013, Pages 823-832

  Forde, Patrick M ^a   Kelly, Ronan J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Esophageal cancer; Genomic; HER2; Mutation; Novel; Targeted; Therapy

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AFLIBERCEPT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PERTUZUMAB; PLACEBO; RAMUCIRUMAB; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MET PROTEIN, HUMAN; MONOCLONAL ANTIBODY; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; VASCULOTROPIN A;

ABDOMINAL PAIN; ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHROMOSOME ABERRATION; DEATH; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL CARCINOMA; GENE AMPLIFICATION; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; LUNG DISEASE; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; MUTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CANCER STAGING; DISEASE FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GENETICS; HUMAN GENOME; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; GENOME, HUMAN; HEPATOCYTE GROWTH FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880683638     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0130     Document Type: Article

References (78)

1. National Cancer Institute. Suveillance Epidemiology and End Results. Available at http://seer.cancer.gov/. Accessed May 28, 2013.
2. Ferlay J, Shin HR, Bray F. GLOBOCAN 2008 Cancer Incidence and Mortality World wide IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; Available at http://globocan.iarc.fr. Accessed July 1, 2013.
3. van Hagen P, Hulshof MC, van Lanschot JJ et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-2084.
4. Agrawal N, Jiao Y, Bettegowda et al. Comparative genoic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012; 2:899-905.
5. Dulak AM, Schumacher SE, van Lieshout J et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-4393.
6. Cui R, Kamatani Y, Takahashi A et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology 2009;137:1768-1775.
7. Hiyama T, Yoshihara M, Tanaka S et al. Genetic polymorphisms and esophageal cancer risk. Int J Cancer 2007;121:1643-1658.
8. Zhuo WL, Zhang YS, Wang Y et al. Association studies of CYP1A1 and GSTM1 polymorphisms with esophageal cancer risk: Evidence-based meta-analyses. Arch Med Res 2009;40:169-179.
9. Eng C, Spechler SJ, Ruben R et al. Familial Barrett esophagus and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 1993;2:397-399.
10. Jochem VJ, Fuerst PA, Fromkes JJ. Familial Barrett's esophagus associated with adenocarcinoma. Gastroenterology 1992;102:1400-1402.
11. Chak A, Ochs-Balcom H, Falk G et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prevention 2006;15:1668-1673.
12. Chak A, Faulx A, Kinnard M et al. Identification of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 2004;99: 2107-2114.
13. Kala Z, Dolina J, Marek F et al. Polymorphisms of glutathione S-transferase M1, T1 and P1 in patients with reflux esophagitis and Barrett's esophagus J Hum Genet 2007;52:527-534.
14. van Lieshout EM, Roelofs HM, Dekker S et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res 1999;59:586-589.
15. Casson AG, Zheng Z, Chiasson D et al. Associations between genetic polymorphisms of phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 2003;27:139-146.
16. Casson AG, Zheng Z, Evans SC et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005;104:730-739.
17. Izzo JG, Wu TT, Wu X et al. Cyclin D1 guanine/ adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Oncol 2007;25:698-707.
18. Gu J, Ajani JA, Hawk ET et al. Genome-widecatalogue of chromosomal aberrations in Barrett's esophagus and esophageal adenocarcinoma: A high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) 2010;3:1176-1186.
19. Varis A, Puolakkainen P, Savolainen H et al. DNA copy number profiling in esophageal Barrett adenocarcinoma: Comparison with gastric adenocarcinoma and esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2001;127:53-58.
20. Bang YJ, Van Gutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
21. Reid BJ, Prevo LJ, Galipeau PC et al. Predictors of progression in Barrett's esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-2848.
22. Hollstein MC, Metcalf RA, Welsh JA et al. Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 1990;87:9958-9961.
23. Casson AG, Mukhopadhyay T, Cleary KR et al. p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 1991;51:4495-4499.
24. Powell EL, Leoni LM, Canto MI et al. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: Evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications. Am J Surg Pathol 2005;29:1497-1504.
25. Goh XY, Rees JR, Paterson AL et al. Integrative analysis of array-comparative genomic hybridisation and matched gene expression profiling data reveals novel genes with prognostic significance in oesophageal adenocarcinoma. Gut 2011;60:1317-1326.
26. Agrawal N, Jiao Y, Bettegowda C et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905.
27. Dulak AM, Schumacher SE, van Lieshout J et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-4393.
28. Abedi-Ardekani B, Dar NA, Mir MM et al. Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia BMC. Cancer 2012;12: 602.
29. Hanawa M, Suzuki S, Dobashi Y et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-1180.
30. Kitagawa Y, Ueda M, Ando N et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res 1996;2:909-914.
31. Wang KL, Wu TT, Choi IS et al. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: Association with poor outcome. Cancer 2007;109: 658-667.
32. Yu WW, Guo YM, Zhu M et al. Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: A meta-analysis. Hepatogastroenterology 2011;58: 426-431.
33. Gonzaga IM, Soares-Lima SC, de Santos PT et al. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer 2012;12:569.
34. Liu QW, Fu JH, Luo KJ, et al. Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma. Dis Esophagus 2011 [Epub ahead of print].
35. Rodriguez CP, Adelstein DJ, Rice TW et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol 2010; 5:229-235.
36. Ruhstaller T, Pless M, Dietrich D et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase IB/II trial (SAKK 75/06). J Clin Oncol 2011;29:626-631.
37. Dahan L, Chibaudel F, Di Fiore P et al. Chemoradiation with FOLFOX plus cetuximab in locally advanced cardia or esophageal cancer: Final results of a GERCOR phase II trial (ERaFOX). Paper presented at: 2011 American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL.
38. Gavine PR, Mooney L, Kilgour E et al. AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 2012;72:2045-2056.
39. Dahan L, Mariette C, Ychou M et al. Neoadjuvant chemoradiotherapy with 5-fluorouracil-cisplatin combined with cetuximab in patients with resectable locally advanced esophageal carcinoma: A prospective phase I/II trial (FFCD-PRODIGE 3)-preliminary phase II results. Paper presented at: 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
40. Tomblyn MB, Goldman BH, Thomas CR Jr et al. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer:Aphase-II study of the SWOG (S0414). J Thorac Oncol 2012;7: 906-912.
41. Crosby T, Hurt C, Falk S et al. SCOPE 1: A phase II/III trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. Paper presented at: American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium; January 24-26, 2013; San Francisco, CA.
42. Yu J, Meng X, Wang JH et al. Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study. Paper presented at: 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
43. Reed CE, Decker PA, Schefter TE et al. Aphase II study of neoadjuvant therapy with cisplatin, docetaxel, panitumumab plus radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Paper presented at: 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
44. Kordes S, Richel D, van Berge MI et al. Multicenter phase II study combining panitumumab with chemoradiation followed by surgery for patients with operable esophageal cancer (PACT-study). Paper presented at: 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
45. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006;24: 1612-1619.
46. Ferry DR, Anderson M, Beddard K et al. Aphase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007;13:5869-5875.
47. Dragovich T, McCoy S, Fenoglio-Preiser CM et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006;24:4922-4927.
48. Hu Y, Bandla S, Godfrey TE et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 2011;24:899-907.
49. Prins MJ, Ruurda JP, van Diest PJ et al. The significance of the HER-2 status in esophageal adenocarcinoma for survival: An immunohistochemical and an in situ hybridization study. Ann Oncol 2013; 24:1290-1297.
50. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
51. Kleespies A, Guba M, Jauch KW et al. Vascular endothelial growth factor in esophageal cancer. J Surg Oncol 2004;87:95-104.
52. Shih CH, Ozawa S, Ando N et al. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000;6: 1161-1168.
53. Shah MA, Ramanathan RK, Ilson DH et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006;24:5201-5206.
54. Shah MA, Jhawer M, Ilson DH et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011;29:868-874.
55. Ohtsu A, Shah MA, Van Cutsem E et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29:3968-3976.
56. Van Cutsem E, de Haas S, Kang YK et al. Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;30:2119-2127.
57. Knox JJ, Wong R, Darling GE et al. Adjuvant sunitinib for locally advanced esophageal cancer: Results of a phase II trial. Paper presented at: 2011 American Society of Clinical Oncology Annual Meeting; June 3-7, 2011; Chicago, IL.
58. Ku GY, Janjigian YY, Shah MA et al. Phase II trial of sorafenib in esophageal and gastroesophageal junction cancer: Response and prolonged stable disease observed in adenocarcinoma. Paper presented at: American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium; January 24-26, 2013; San Francisco, CA.
59. Fuchs CS, Tomasek J, Cho JY et al. REGARD: A phase III, randomized, double-blinded trial of ramucirumab and best supportive care versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum-and/or fluoropyrimidine-containing combination therapy. Paper presented at: American Society of Clinical Oncology 2013 Gastrointestinal Cancers Symposium; January 24-26, 2013; San Francisco, CA.
60. Gold PJ, Goldman B, Iqbal S et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: A phase II Southwest Oncology Group Study (S0415). J Thorac Oncol 2010;5:1472-1476.
61. Bendell JC, Meluch A, Peyton J et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012;10:430-437.
62. Enzinger PC, Burtness B, Hollis D et al, CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. Paper presented at: 2010 ASCO Annual Meeting; June 4-8, 2010; Chicago, IL. 74. Waddell TS, Chau I, Barbachano Y et al. A randomized multicenter trial of epirubicin, oxaliplatin, andcapecit-abine plus panitumumab in advanced esophagogastric cancer. Paper presented at: 2012 American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
63. Adelstein DJ, Rodriguez CP, Rybicki LA et al. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction. Invest New Drugs 2012;30:1684-1689.
64. Ferry DL et al. Phase III multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy, COG (Cancer Oesophagus Gefitinib). Paper presented at: 2012 European Society for Medical Oncology Annual Meeting; September 28-October 2, 2012; Vienna, Austria.
65. Wainberg ZA, Lin LS, DiCarlo B et al. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction. Br J Cancer 2011;105:760-765.
66. Tuynman JB, Lagarde SM, TenKate FJ et al. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. Br J Cancer 2008;98:1102-1108.
67. Kato H, Arao T, Matsumoto K et al. Geneamplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma Int J Oncol 2013;42: 1151-1158.
68. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011;29:4803-4810.
69. Yap TA, Harris D, Barriuso J et al. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. Paper presented at: 2008 American Society of Clinical Oncology Annual Meeting; May 30-June 3, 2008; Chicago, IL.
70. Garcia A, Rosen L, Cunningham CC et al. Phase 1 study of ARQ197, aselective inhibitor of thec-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. Paper presented at: 2007 American Society of Clinical Oncology Annual Meeting; June 1-5, 2007; Chicago, IL.
71. Schmitt JM, Sommers SR, Fisher W et al. Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Group. J Thorac Oncol 2012;7:760-763.
72. Ilson DH, Kelsen D, Shah M et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer 2011;117:1409-1414.
73. Shah MA, Wainberg ZA, Catenacci DV et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One 2013;8:e54014.
74. Ivesen T, Donehower RC, Davidenko I et al. Safety and efficacy of epirubicin, cisplatin and capecitabine plus rilotumumab as first-line treatment for unresectable locally advanced or metastatic gastric or esophagogastric junction adenocarcinoma. Paper presented at: European Society of Medical Oncology Annual Meeting; September 23-27, 2011; Stockholm, Sweden.
75. Oliner KS, Tang R, Anderson A et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumabor placebo in combination with epirubicin, cisplatin and capecitabine in patients with locally advanced or metastatic gastric or esophagogastric junction cancer. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 1-5, 2012; Chicago, IL.
76. Matsumoto K, Arao T, Hamaguchi T et al. FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 2012;106: 727-732.
77. Yashiro M, Shinto O, Nakamura K et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int J Cancer 2010;126:1004-1016.
78. Satoh T, Yamada Y, Muro K et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol 2012;69: 439-446.